Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Quantification of piroxicam and 5 `-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration

Full text
Calvo, Adriana Maria [1] ; Santos, Gabriel Mulinari [1] ; Dionisio, Thiago Jose [1] ; Marques, Maria Paula [2] ; Brozoski, Daniel Thomas [1] ; Lanchote, Vera Lucia [2] ; Raposo Fernandes, Maria Helena [3] ; Cardoso Faria, Flavio Augusto [1] ; Santos, Carlos Ferreira [1]
Total Authors: 9
[1] Univ Sao Paulo, Bauru Sch Dent, Dept Biol Sci, BR-17012901 Sao Paulo - Brazil
[2] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, BR-17012901 Sao Paulo - Brazil
[3] Univ Porto, Fac Dent, Lab Bone Metab & Regenerat, Rua Campo Alegre 823, P-4100 Oporto - Portugal
Total Affiliations: 3
Document type: Journal article
Source: Journal of Pharmaceutical and Biomedical Analysis; v. 120, p. 212-220, FEB 20 2016.
Web of Science Citations: 2

Saliva sampling used to quantify piroxicam and 5'-hydroxypiroxicam is a noninvasive and painless method when compared to sequential blood sampling. For that, a rapid, selective and sensitive liquid chromatography-tandem mass spectrometric method for simultaneous determination of piroxicam and 5'-hydroxypiroxicam in saliva and human plasma was developed and validated. Piroxicam and its major metabolite were separated using a LiChroCART 125-4 RP Select-B Sorbent C18 column using a mixture of methanol and 2% phosphoric acid (pH 2.7) (70:30, v/v) for the mobile phase with a flow injection of 1 mL/min. The run time was 4 min. Volunteers had saliva and blood sampled before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 h after taking a 20 mg oral dose of piroxicam. The pharmacokinetic parameters of piroxicam in plasma samples were as follows: AUC(0-72) (64819 h ng/mL), predicted clearance (0.2 L/h), distribution volume (14.8 L), elimination half-life (50.7 h) and saliva/plasma concentration ratio (0.003). The{''}estimation of all pharmacokinetic parameters for 5'-hydroxypiroxicam would require collections beyond 72 h; however, it was possible to quantify the mean maximum concentration (133 ng/mL), time to peak concentration (53.6 h), mean AUC(0-72) (6213 h ng/mL), predicted clearance (110.31.1h) and saliva/plasma concentration ratio (0.04). The developed methods proved effective and sensitive for determining the lower quantification limit of piroxicam in plasma (6.1 ng/mL) and saliva (0.15 ng/mL) and of 5'-hydroxypiroxicam in plasma (1.2 ng/mL) and saliva (0.15 ng/mL). (C) 2015 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 09/17851-8 - Influence of cytochrome P450 (CYP2C9) genotype on the clinical efficacy and pharmacokinetics of piroxicam after lower third molar surgery
Grantee:Adriana Maria Calvo
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 14/17803-1 - Influence of genotype of cytochrome P450 (CYP2C9) on the clinical efficacy and pharmacokinetics of Piroxicam after lower third molar surgery
Grantee:Carlos Ferreira dos Santos
Support type: Regular Research Grants
FAPESP's process: 15/10198-8 - Study of the pharmacogenetics of the cytochrome p450 and pharmacokinetics of piroxicam in saliva samples by mass spectrometry
Grantee:Gabriel Mulinari dos Santos
Support type: Scholarships in Brazil - Scientific Initiation